Across 189 unique European colorectal cancer trials with a Phase II or Phase III component, 55 trials used at least one CRO or outsourced operational provider, equal to 29.1%. CRO use was most strongly associated with EU/CTIS coordination complexity: 16 of 16 trials spanning 7 or more countries used CROs, compared with only 9 of 121 single-country trials.
At provider-group level, ICON appeared in 16 of 55 CRO-supported trials, followed by Almac in 15, Parexel in 14, IQVIA in 14, and PPD / Thermo Fisher in 12. Percentages below use 55 CRO-supported trials as the denominator; one trial can use multiple providers.
The active provider market is split between full-service CRO groups and specialist operational vendors. For sponsors planning EU colorectal cancer submissions, the most visible full-service CRO groups are ICON, Parexel, IQVIA, PPD / Thermo Fisher, Syneos Health, Medpace, and Fortrea.
Country count was the clearest CRO trigger. CROs were used in 9 of 121 single-country trials, 15 of 30 trials with 2–3 countries, 15 of 22 trials with 4–6 countries, and 16 of 16 trials with 7 or more countries.
For CTIS-era European colorectal cancer trials, CRO demand rises sharply once a study becomes multi-country. The inflection point is 2–3 countries, and CRO use becomes universal in the dataset at 7 or more countries.
CRO use was low in single-site trials at 2 of 27 trials, then rose to 8 of 28 trials with 2–5 sites, 11 of 32 trials with 6–10 sites, and 31 of 91 trials with 11 or more sites.
Site count matters, but it is weaker than country count. CRO involvement increases once trials move beyond 1 site, then plateaus around one-third of studies at 6 or more sites.
Participant count was not the strongest CRO-use signal. CROs appeared in 13 of 49 trials with fewer than 50 participants, 19 of 67 trials with 50–149 participants, 14 of 39 trials with 150–299 participants, and 8 of 33 trials with 300 or more participants.
CRO need in colorectal cancer trials is better predicted by cross-border and disease-complexity burden than by participant count alone. The highest participant band did not have the highest CRO rate.
Basket or multi-tumour trials that included colorectal cancer had the highest CRO rate at 21 of 34 trials. Metastatic or advanced colorectal cancer trials used CROs in 23 of 101 trials, rectal cancer trials in 9 of 41, and colon cancer trials in 2 of 13.
CRO use is highest when colorectal cancer is part of a broader multi-tumour protocol, where sponsors must coordinate multiple tumour populations, endpoints, countries, and vendors within a single CTIS submission strategy.
Trials with one disease label used CROs in 16 of 90 cases. CRO use increased to 13 of 24 trials with 3–4 disease labels and 14 of 21 trials with 5 or more disease labels.
Disease-label complexity is one of the strongest outsourcing signals. Multi-indication oncology protocols are much more likely to require external regulatory, data, laboratory, imaging, and site-coordination capacity.
Among the 55 CRO-supported trials, readable outsourced functions most often involved data systems, electronic data capture, eCOA, eTMF, CTMS, IVRS or IRT in 26 trials; clinical operations, monitoring or start-up in 25 trials; central lab, biomarker or PK work in 19 trials; and imaging or central review in 15 trials.
The most common outsourced needs are operational infrastructure rather than only full trial management. Data systems, clinical operations, central lab/biomarker testing, and imaging are the clearest functional entry points for CRO and specialist-provider support.
CRO-supported colorectal cancer trials generated 247 country-level CTIS Part II processing entries. Spain accounted for 42 CRO-supported trial-country entries, Italy 33, France 30, Belgium 26, Germany 25, and the Netherlands 22. Median country-level CTIS processing time was 69 days in CRO-supported entries versus 186.5 days in non-CRO entries.
Spain, Italy, France, Belgium, Germany, and the Netherlands are the most important operational geographies for CRO-supported colorectal cancer CTIS submissions. These are the countries where sponsor-side CRO support is most likely to intersect with site activation, Part II documentation, and country-level trial execution.
Sponsor type was one of the strongest adjacent predictors. Pharmaceutical-company sponsors used CROs in 52 of 69 trials, while hospital or healthcare-facility sponsors used CROs in only 2 of 92 trials. Patient organizations used CROs in 1 of 10 trials; educational institutions and laboratory/research sponsors used CROs in 0 of 18 combined trials.
Commercial sponsors are the main buyers of CRO capacity in this colorectal cancer cohort. Academic and hospital-led studies dominate trial count, but they rarely list CROs in the sponsor-declared CTIS third-party structure.
CRO refers to sponsor-declared CRO or outsourced operational provider entries in the CTIS sponsor variable. CTIS means Clinical Trials Information System. Part II refers to the country-level EU/EEA assessment component covering local and site-related documentation. Percentages are trial-level unless explicitly labelled as country-level CTIS entries.
For colorectal cancer Phase II/III trials in Europe, CRO need is highest when the study becomes cross-border, multi-disease, commercially sponsored, or operationally vendor-heavy. The strongest practical signal is not patient count; it is CTIS coordination burden across countries, sites, and outsourced data, lab, imaging, and clinical-operation functions.